Imv Inc (TSE:IMV) – Analysts at B. Riley boosted their Q3 2019 EPS estimates for shares of IMV in a research note issued on Monday, August 12th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.12). B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for IMV’s Q4 2019 earnings at ($0.12) EPS, FY2019 earnings at ($0.45) EPS, FY2020 earnings at ($0.57) EPS, FY2021 earnings at ($0.82) EPS, FY2022 earnings at ($0.55) EPS and FY2023 earnings at ($0.07) EPS.
TSE:IMV opened at C$3.71 on Wednesday. The firm’s 50-day moving average is C$3.78 and its 200-day moving average is C$5.01. IMV has a 52-week low of C$3.06 and a 52-week high of C$8.49. The company has a debt-to-equity ratio of 44.63, a quick ratio of 5.01 and a current ratio of 5.74. The company has a market cap of $167.53 million and a price-to-earnings ratio of -7.04.
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.